期刊文献+

子宫内膜样腺癌中COX-2和PTEN蛋白表达及临床意义 被引量:1

下载PDF
导出
摘要 目的:检测COX-2蛋白、PTEN蛋白在子宫内膜样腺癌中的表达,探讨二者与组织分级和临床分期的关系以及在子宫内膜样腺癌转移浸润中的意义。方法用免疫组织化学技术和图像分析法检测150例子宫内膜样腺癌、150例正常子宫内膜组织中COX-2蛋白和PTEN蛋白表达。结果 PTEN蛋自在子宫内膜样腺癌组织中的阳性表达率为32.7%,与正常子宫内膜组织(86.0%)比较差异显著(P<0.05);COX-2蛋白在子宫内膜样腺癌组织中的阳性表达率为74.7%,与正常子宫内膜组织(27.3%)相比差异显著(P<0.05);PTEN蛋白与子宫内膜样腺癌的组织学分级及肌层浸润深度有关(P<0.05);COX-2蛋白与子宫内膜样腺癌的组织学分级及淋巴转移度有关(P<0.05)。 COX-2蛋白阳性表达与COX-2蛋白阳性表达呈负相关(r=-0.742,P<0.01)。结论 COX-2蛋白、PTEN蛋白在子宫内膜样腺癌组织中均异常表达,结合临床病理参数可作为预测子宫内膜样腺癌恶性程度及预后判定的客观指标。
作者 谭育青
出处 《医学信息(医学与计算机应用)》 2014年第4期334-334,共1页 Medical Information
  • 相关文献

参考文献5

二级参考文献64

  • 1Slomovitz BM,Lu KH,Johnston T,et al.A phase Ⅲ study of oral mammalian target of rapamycin (moTOR) inhibitor,RAD001 (everolimus),in patients with recurrent endometrial carcinoma (EC)[C].2008 ASCO Annual Meeting Proceedings (Clinical Science Symposium).
  • 2Oza AM,Elit L,Provencher J,et al.A phase Ⅲ study of temsirnlimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy:NCIC CTG IND 160b[C].2008ASCO Annual Meeting Proceedings(Post Meeting Edition).
  • 3Nagai N,Oshita T,Fujii T,et al.Prospective analysis of DNA ploidy,proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer[J].Oncol Rep,2000,7(3):551-559.
  • 4Brys M,Semezuk A,Reehberger T,et al.Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium[J].Oncol Rep,2007,18(1):261-265.
  • 5Albitar L,Laidler LL,Abdallah R,et al.Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type Ⅰ and Ⅱ tumors[J].Mol Cancer Ther,2005,4(12):1891-1899.
  • 6Leslie KK,Laidler L,Albitar L,et al.Tyrosine kinase inhibitors in endometrial cancer[J].Int J Gynecol Cancer,2005,15(3):409-411.
  • 7Leslie KK,Sill MW,Darcy KM,et al.Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR,EGFR mutations,and tumor markers in a Gynecologic Oneology Group phase Ⅱ trial of persistent or recurrent endometrial cancer[J].J Clin Oncol,2009,27(suppl):15.
  • 8Jasas KV,Fyles A,Elit L,et al.Phase Ⅱ study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer:NCIC CTG IND-148[J].J Clin Oncol,2004,22(suppl):453-453.
  • 9Nimeiri HS,Oza AM,Morgan RJ,et al.Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS):A phase Ⅱ trial of the University of Chicago,PMH,and California phase Ⅱ consortia[C].2008 ASCO Annual Meeting Proceedings (Post Meeting Edition).
  • 10Slomovitz BM,Ramnndetta LM,Johnston T,et al.A phase I study of imatinib mesylate and paclitaxei in patients with advanced (stage ⅢC/IV) or recurrent uterine papillary serous carcinoma (UPSC)[J].J Clin Oncol,2007,25(suppl):16025.

共引文献49

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部